Thank you so much. It's a pleasure to be here and to present our new suggested financing. And while doing that, I will give you a background on Cantargia and explain why we're undertaking this financing now and what we aim to achieve. So for those of you who don't know Cantargia, we are an IL1RAP antibody company and we have two clinical programs right now, one in cancer and one in autoimmune inflammatory diseases. And we have made good progress in both programs. Nadunolimab. We have treated more than 300 patients with cancer, and we have interesting data to which we will come back. And we also have a randomized phase two trial ongoing in triple-negative breast cancer and in CAN10. We are still in Phase 1, but we are generating a lot of interest from the outside world, since this is really in a very interesting area where the focus for drug development is right now. And we'll come into that one as well. With this rights issue, we will extend our runway and we will come back to that later on as well. I would also like to point out that we have a very good IP on our programs, with the cancer program Nadunolimab having composition of matter patents until 2035. Unless extensions are granted with extended market exclusivity, the corresponding CAN10 patents remain valid until at least 2041. So? So, the pipeline looks like this: Nadunolimab. Uh, we have most of the data in pancreatic cancer, in non-small cell lung cancer, solid phase two data, and the triple negative breast cancer trial is ongoing. In the near future, we also expect to start a fully financed trial in leukemia. In CAN10, the lead indications would be Hidradenitis Suppurativa, which is a quite common dermatological disease, and also a more orphan type of disease like systemic sclerosis. And we're making progress in preparations for Phase 2. And finally, our CAN10 program encompasses a range of new antibodies that can be used either as diagnostics, which is highly relevant to our current activities, but also for novel follow-up concepts like antibody-drug conjugates or bispecific antibodies. So, if we start with the CAN10 program, it focuses on autoimmune inflammatory diseases. CAN10. CAN10 is a unique antibody because it blocks three different disease-promoting cytokines at the same time: IL-1, IL-33, and IL-36. And CAN10 has been designed to do that by binding to a specific part of IL1RAP, which is connecting to the receptors for these cytokines. And thereby the interactions are blocked, and the inflammatory signals are blocked. And we've seen very potent effects in several animal models of a large number of diseases. So, we're very confident that we have a potent drug which will generate significant interest. If we then go into the ages of Hidradenitis Suppurativa. It is a disease that is more common than most people think. It's affecting about 1% of the population in the Western world and starts with inflammation in hair follicles, which at that early stage can be treated with antibiotic paste or steroids. But once it gets more advanced, these inflamed hair follicles develop into something called draining tunnels, which are on the inside of the skin. And at that point in time, you will start systemic treatment with antibodies like Humira or recently with anti-IL-17. But the important message here is that even though these biological treatments are effective, they still manage to elicit a response from only about 50% of patients, leaving a significant medical need, especially in the later-stage populations. What has increased the interest for Cantargia here is two independent clinical trials, one from Boehringer Ingelheim using their IL-36 blocking antibody Spesolimab, which has shown efficacy especially on the draining tunnels, a very important part of the disease. The second drug, which has shown a great effect, is an IL-1 blocker, Lutikizumab from ABBVIE, which has shown effects on the more inflammatory part of the disease. And good data on what's called the high score of 50 and high score 75. And you can see the results to the right in this slide. So, the Spesolimab has a clear effect on the draining tunnels. And let's consider a composite score called IHS4. While Lutikizumab has demonstrated strong data on both the high score 50 and high score 75. So, to put this into context, IL1RAP is a co-receptor for both IL-1 and IL-36, and CAN10 blocks these. These both of these cytokines extremely potently. So we believe that we have a unique opportunity here to attack two different parts of the disease, both the inflammatory part as well as the draining tunnels. And thereby, we will be highly competitive with the other two drugs, which are based on the positive data and taken forward in clinical development for Hidradenitis Suppurativa by AbbVie and Boehringer Ingelheim.
So, we are really excited to go forward here and to quickly comment on where we stand. So with CAN10, we have completed the single dose segment in healthy volunteers, and we have not observed any safety signals, which is obviously the purpose of this type of Phase 1 trial. But another very positive thing is that we have documented very clear dose-dependent receptor occupancy. So, the higher doses we treat with, the more CAN10 antibody will bind to disease-promoting immune cells, both monocytes as well as neutrophils. And as you can see down to the left, we clearly achieve full receptor occupancy, even at doses that are lower than those intended for upcoming clinical trials. And if you look to the right, we have taken whole blood from these individuals. We have stimulated the whole blood with IL-36 and then measured how responsive the cells are. And what you can see is that both day one and day eight, these cells are insensitive to IL-36 once they have been stimulated with or exposed to CAN10 in the patients. So again, a great result. And so we believe that we really squeezed out as much as we possibly could hope for in this phase part. And we're now doing multiple dosing in patients with psoriasis. And we expect to present data from those trials as they mature during the first half of next year and most likely sequentially.
So when the cancer program. So, IL1RAP is also overexpressed on a large number of solid tumor types, which is really interesting. So you can say that somewhere between 70 to 90% of patients have some kind of overexpression of IL1RAP, and it's overexpressed both on the cancer cells and in the tumor stroma, typically on immune cells or fibroblasts. And this is of relevance to the work we're doing both in pancreatic cancer and lung cancer. And I will show you a little bit more of that in a second. So, as most of you know, we have positive data in pancreatic cancer. We have treated newly diagnosed patients with metastatic pancreatic cancer using a combination therapy. Typically, these patients would very quickly start therapy with a chemotherapy like Gemcitabine Abraxane. And we've added nadunolimab to this regimen and studied 73 patients across several European countries and approximately 15 different hospitals. So clearly a mix of patients. But we consistently see good results. And if you look to the left, you can see that the patients had a median survival of 13.2 months. This is somewhere 3 to 4 months longer than you would expect from gemcitabine. Abraxane.
So, it is clearly associated with a survival benefit compared to what you would expect from historical controls in this trial. But what we also see, which you can observe on the right, is that when you measure the tumor size in these patients before and during therapy, quite a few of them experience a 50% or more reduction in tumor size. And this is a much better result than you would expect from chemotherapy alone. So the patients are clearly doing well when we add Nadunolimab to these patients. And what is also really interesting is that, since we have a targeted therapy, we have measured how much IL1RAP there is on the tumor cells. Then, we aimed to determine if there is a correlation between high and low IL1RAP levels. And there is a clear correlation. So, the patients who had the highest level of IL1RAP on their cancer cells are really the ones who are the strongest drivers of this efficacy signal. And this is really positive from two aspects. So the first one is that if our drug works, you probably should expect these patients to do better. But it's even better than that; if you have a high IL1RAP level, that's often correlated with very aggressive tumor mutations called KRAS mutations. And these patients have a worse prognosis than those with low IL1RAP. So in fact, you can say that patients with worse prognosis are the ones that are really benefiting the most in this trial, and this is clearly creating interest. And we will come back to how we are going to deliver on this.
And then a second thing we discovered in this trial, which is further increasing the interest, is that chemotherapy also stimulates immune cells in nerve cells. And so, the chemotherapy, by stimulating these immune cells, will induce something called neuropathy. And what we have seen is that since Nadunolimab is an IL-1 blocker, we can observe that the higher the doses of Nadunolimab, the more pronounced the effect is on neuropathy. You can see that to the right. So the dose levels that we intend to use in the clinical trials are clearly delaying the onset of neuropathy. And it's also causing fewer patients to actually suffer from neuropathy. So this is really a great result. If you combine this in pancreatic cancer, you see that you both increase life expectancy and also reduce some of the serious side effects of chemotherapy. The result is clearly highly interesting in a very difficult-to-treat patient group.
And then moving into non-small cell lung cancer.
So what we see here is that again there is a subgroup of patients that are doing tremendously well. And that's what's called the non-squamous non-small cell lung cancer. And what? And that's a majority of the non-small cell lung cancer patients. So what we also see is that in this group of patients, we are doing tremendously well in patients that are second-line to immune therapy like the PD-1s. And one reason why we're getting such good effects in this patient population can be seen to the right. It may be difficult to see, but what we've done is stain the tumors from both patients who have not received immune therapy and those who have. And what we see is that once we stop responding to immune therapy, there has been an increase in IL1RAP positive immune cells in the tumor area, and that can most likely be linked to the unresponsiveness of the immune therapy. So our hypothesis is that once the drug gets into the tumor, it interacts with these immune cells, which then helps get our own immune system back on track. And this is also a result which is generating significant interest. But also, it's a highly competitive area. And for both, let's say, the pancreatic cancer opportunity as well as the non-small cell lung cancer opportunity. We have been out talking to various interested parties, so it could be specialist physicians, it can be investors, it can be pharma companies. And I think that the signal we're getting is that we have highly interesting data in both these indications, but we also live in a very competitive world. And to remain competitive, it's very clear we need to work with the patients that are most likely to respond. And to do that, we need robust diagnostic tests. And we have made initial progress in the development of these diagnostic tests. And we still have some validation work to be done. But we clearly believe that once they are ready, we will be in a much stronger position to go into late-stage development in both of these indications. So I think we will have very interesting discussions during 2025 now that we can deliver on this very important aspect of the program, and also the good safety and the reduction of neuropathy is driving the interest here as well. And as an investor, obviously you would like to see more data and various data being generated in additional cancers in the future, both triple negative breast cancer and leukemia. So I think this program is highly relevant. And we're strengthening now by having methods to select the patients most likely to respond. So again, to look at what type of milestones we have in front of us. So we have redesigned or are in the process of redesigning the pancreatic cancer trial. We will have new discussions with the FDA once we have advanced to work a little bit further on the diagnostic methods and to be ready to start. Though robust and solid clinical trials are expected during H2 next year in triple negative breast cancer. The randomized Phase 2 trial is ongoing. We expect the top-line data late in H1 this year, focusing on leukemia. We are very proud that we received the highly prestigious grant from the US Department of Defense to collaborate with MD Anderson Hospital at our cancer center in Houston. That trial is being prepared, and we hope to get the first patients in during this year. And CAN10, we presented lots of positive data during 2024, and I don't see any reason why we shouldn't continue to do that. So we will continue to present data on the MAD segment during H1, and we will conclude the MAD segment during H1 to be ready to start Phase 2 during H2 next year and again for the CAN10 program.
We have also been out talking to Coles and to investors and pharma companies. The program is generating a lot of interest. It's still a bit early, but once we're getting closer to the start of phase two, I think we'll be in some very interesting discussions here. And we also have received very valuable feedback on where to go and how to position the drug in the best possible way. So by that, we're now coming into the rationale why we're doing this rights issue. We've had numerous discussions and I can say we hoped to be in a position to present some kind of partnership or other type of solutions. But all of these discussions have taken longer than expected or have ended up in various types of proposals which we do not think are in the interest of Cantargia shareholders. And in order to keep the momentum and continue to intensify the development. We're not pursuing this rights issue, and I believe we are doing so from a position of strength, supported by promising data from 300 cancer patients, with CAN10 being halfway through phase one and showing very interesting results, which influences our use of proceeds. Obviously, we have ongoing clinical trials and ongoing engagements. But one really, really important piece here is to develop this diagnostic method which has to be robust enough to measure expression of IL1RAP. So it can be used to select patients. And an interesting aspect here as well is that such an assay is not only important in pancreatic cancer, it may be adapted and may be a super important tool in non-small cell lung cancer. And as we advance CAN10, I'm sure these types of questions will arise as to whether we should pre-select patients with higher levels of IL1RAP, for instance, in skin or in various other types of tissues. And again, having this assay in place would be a highly competitive advantage. In CAN10, we are also undertaking a number of activities to strengthen ourselves ahead of Phase 2 and to be attractive for continued commercial discussions. And there are a number of aspects here. So we have toxicity studies. What we need to do to get more patient tissue to do more functional translational studies, for instance, in skin from patients with MS. . It's really going to be valuable ahead of the phase two trial. The product is also in a phase where we need to focus more on CMC development and production, which is obviously a significant part of this fundraising. And we're also planning to be in a strong position once we submit the application for an IND in the US, which is planned for the first half of next year. So by that, I would like to hand over to Patrick to go through more of the details around this rights issue. And then we're very happy to take questions.